NEW YORK (GenomeWeb) – Caprion Bioscience is investigating whether a five-protein panel can be useful in early detection and predicting progression in Alzheimer's disease.

The company said this week that it has entered in a collaboration with the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium to measures proteins in its CNS ProteoCarta MRM biomarker panel in longitudinally collected samples from some 200 subjects from the Alzheimer's Disease Neuroimaging initiative.